Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial

Documenti analoghi

• The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
  di: Chirgwin, Jacquie, et al.
  Pubblicazione: (2011)
• Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
  di: Chirgwin, Jacquie H., et al.
  Pubblicazione: (2016)
• Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study
  di: Colleoni, Marco, et al.
  Pubblicazione: (2011)
• Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
  di: Metzger Filho, Otto, et al.
  Pubblicazione: (2015)
• Evaluating Letrozole and Tamoxifen Alone and in Sequence for Postmenopausal Women with Steroid Hormone Receptor-Positive Breast Cancer: the BIG 1-98 Randomized Clinical Trial at 8.1 years Median Follow-Up
  di: Regan, Meredith M., et al.
  Pubblicazione: (2011)